Takeda engaged in antitrust scheme to delay generic constipation drug: U.S. jury
The verdict is the first time a jury has found a pharmaceutical company liable in class-action litigation over what is called a 'pay-for-delay' agreement with generic rivals.
2 outlets in our directory ran this story, first to last over 1 hour. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
- ▪ Japan’s Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds — Investing.com — News
Japan Times publishes from Japan and files mainly under world. We currently carry 650 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Japan Times |
| Canonical URL | https://www.japantimes.co.jp/business/2026/05/19/companies/takeda-antitrust-generic-constipation-drug/ |
| Publication time | Tue, 19 May 2026 12:26:00 +0900 |
| Retrieval time | 2026-05-19T03:29:57.215Z |
| Last seen | 2026-05-19T03:29:57.215Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | None yet |
| Summary source text | contentText |
| Citation coverage | No WeSearch summary has been generated for this story yet. |
| Cluster | 0ZWaVESDLPBx · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Takeda Pharmaceutical headquarters in Tokyo. The company said it will "vigorously pursue" an appeal after a U.S. jury on Monday found the company liable for causing about $885 million in damages by delaying a generic version of its constipation drug through an anticompetitive scheme. | BLOOMBERG
Excerpt limited to ~120 words for fair-use compliance. The full article is at Japan Times.
Discussion
0 commentsMore from Japan Times
